HMPL-653
/ Hutchmed
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 04, 2025
HUTCHMED Highlights Clinical Data to be Presented at…the CSCO Annual Meeting 2025
(GlobeNewswire)
- "Clinical data of HMPL-653, a novel, selective and potent CSF-1R inhibitor, from a first-in-human Phase I study in patients with tenosynovial giant cell tumor in China will be presented for the first time at the CSCO Annual Meeting 2025."
P1 data • Tenosynovial Giant Cell Tumor
September 16, 2023
HMPL-653, a highly potent and selective CSF-1R inhibitor, targeting both tumor cells and tumor microenvironment.
(AACR-NCI-EORTC 2023)
- No abstract available
Biomarker • Tumor cell • Tumor microenvironment • Oncology
March 14, 2022
Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
(clinicaltrials.gov)
- P1 | N=113 | Recruiting | Sponsor: Hutchison Medipharma Limited
New P1 trial • Giant Cell Tumor of Bone • Immunology • Oncology • Solid Tumor • Tenosynovial Giant Cell Tumor
January 19, 2022
HUTCHMED Initiates a Phase I Trial of HMPL-653 in Patients with Advanced Malignant Solid Tumors and TGCT in China
(GlobeNewswire)
- "HUTCHMED (China) Limited...announces that it has initiated a Phase I trial in China of HMPL-653, an investigational novel, highly selective, and potent colony-stimulating factor 1 receptor ('CSF-1R') inhibitor. The first patient received their first dose on January 18, 2022. The Phase I trial is a multicenter, open-label, single-arm study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-653 in the treatment of patients with advanced or metastatic solid tumors and tenosynovial giant cell tumors ('TGCT')."
Trial status • Oncology • Solid Tumor
1 to 4
Of
4
Go to page
1